HCWB Stock Overview
A clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
HCW Biologics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.77 |
| 52 Week High | US$2.52 |
| 52 Week Low | US$0.28 |
| Beta | 0.84 |
| 11 Month Change | 66.49% |
| 3 Month Change | 63.83% |
| 1 Year Change | -25.96% |
| 33 Year Change | -73.36% |
| 5 Year Change | n/a |
| Change since IPO | -87.78% |
Recent News & Updates
Shareholder Returns
| HCWB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -37.9% | 2.5% | 2.2% |
| 1Y | -26.0% | 16.1% | 31.6% |
Return vs Industry: HCWB underperformed the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: HCWB underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| HCWB volatility | |
|---|---|
| HCWB Average Weekly Movement | 92.4% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: HCWB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: HCWB's weekly volatility has increased from 48% to 92% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 45 | Hing Wong | www.hcwbiologics.com |
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company’s lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment.
HCW Biologics Inc. Fundamentals Summary
| HCWB fundamental statistics | |
|---|---|
| Market cap | US$34.30m |
| Earnings (TTM) | -US$37.33m |
| Revenue (TTM) | US$3.50m |
9.8x
P/S Ratio-0.9x
P/E RatioIs HCWB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HCWB income statement (TTM) | |
|---|---|
| Revenue | US$3.50m |
| Cost of Revenue | US$7.61m |
| Gross Profit | -US$4.12m |
| Other Expenses | US$33.21m |
| Earnings | -US$37.33m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.84 |
| Gross Margin | -117.76% |
| Net Profit Margin | -1,067.83% |
| Debt/Equity Ratio | -127.2% |
How did HCWB perform over the long term?
See historical performance and comparison